1
00:00:00,000 --> 00:00:04,667
Bremelanotide, also known as PT-141, is a melanocortin receptor agonist.

2
00:00:04,667 --> 00:00:09,333
Its approved US product, Vyleesi, has a specific sexual-health indication.

3
00:00:09,333 --> 00:00:15,208
The label covers acquired, generalized hypoactive sexual desire disorder in premenopausal women under

4
00:00:15,208 --> 00:00:20,292
defined conditions. It is not an approval for general sexual-performance enhancement.

5
00:00:20,292 --> 00:00:24,542
Two randomized, placebo-controlled trials assessed desire and associated distress.

6
00:00:24,542 --> 00:00:31,208
Nausea was common, and the label includes important warnings about blood pressure and skin pigmentation.

7
00:00:31,208 --> 00:00:37,875
Clinical evidence for the approved product does not validate a differently formulated spray or research

8
00:00:37,875 --> 00:00:43,750
vial. The population, diagnostic criteria, route, and safety restrictions remain essential parts of

9
00:00:43,750 --> 00:00:47,250
interpreting the findings.